Shares of Clearpoint Neuro cratered 20.2% to $12.28 after the brain-surgery device maker reported second-quarter results that exposed a widening gap between its ambitious long-term vision and near-term financial reality. The selloff raises a pointed question: how long can investors fund the company's bet on brain-delivered gene therapies before the cash runs out?

The Numbers Missed on Nearly Every Line

Revenue came in at $10.88 million, up 18% year-over-year, but the loss per share ballooned to -$0.38 versus -$0.21 a year ago.

That was $1.83 million below the consensus revenue estimate of $12.73 million, while the EPS miss overshot the expected -$0.29 loss by 31%. The prior quarter had delivered $12.1 million in revenue with 43% growth — making this a sharp sequential deceleration.

The Drug Delivery Engine Stalled

Biologics and drug delivery revenue — the segment central to the company's long-term thesis — declined 15% to $4.0 million, mainly because a large prior-year customer order didn't repeat.

Management blamed slower-than-expected ramp of its new preclinical laboratory, which was still under construction during the quarter.

CEO Joe Burnett said he expects drug delivery revenue to return to growth in the second half of 2026 — a promise investors clearly aren't taking at face value.

Guidance Got Cut and the Cash Cushion Is Thinning

Full-year 2026 revenue guidance was slashed to $48–$52 million , down from the previously affirmed $52–$56 million range.

Meanwhile, operating expenses surged 51% to $17 million, pushing the operating loss to $10.2 million.

Most alarming: cash fell to $29.4 million from $45.9 million at the start of the year — a $16.5 million burn in six months with no profitability in sight. Analysts don't expect the company to become profitable within the next three years.

The Big Bet Demands Patience the Market Isn't Showing

Clearpoint presented a strategy targeting $500 million in annual revenue through brain-focused cell and gene therapy delivery.

The company touts more than 60 active biopharma partners, many now under FDA expedited review. But at the current burn rate, Clearpoint has roughly four to five quarters of runway. Unless drug delivery revenue inflects or the company raises capital — likely at a dilutive price — the $500 million vision may need to survive on significantly less fuel than planned.